The headline beat is significant but driven by a one-time $55.7M licensing fee, not core ORLADEYO acceleration. ORLADEYO guidance was maintained, not raised, suggesting limited upside to the base business. The lowered opex guidance and pipeline rationalization are credit-positive for cash flow. Watch for navenibart ALPHA-ORBIT data in Q3 2027 as the next major catalyst; the pediatric ORLADEYO pellet launch is a near-term volume driver to monitor.
Price Chart
Executive Summary
BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating the $183.3M estimate by 19.1%. The beat was driven by a $55.7M navenibart licensing fee from Neopharmed Gentili, while core ORLADEYO revenue grew only 1% YoY to $158.2M. The company raised total revenue guidance to $690M-$715M and lowered non-GAAP opex guidance, but maintained ORLADEYO guidance at $625M-$645M, signaling the core business is not accelerating.
Key Financial Metrics
Key Facts
- GAAP EPS of $0.30 beat consensus of $0.23 by 30.4%
- Total revenue of $218.3M beat consensus of $183.3M by 19.1%
- ORLADEYO revenue of $158.2M grew only 1% YoY (10% on comparable basis ex-Europe)
- Recognized $55.7M of navenibart licensing revenue from Neopharmed Gentili upfront payment
- Raised full-year 2026 total revenue guidance to $690M-$715M (from $635M-$660M)
- Maintained ORLADEYO revenue guidance at $625M-$645M
- Lowered non-GAAP operating expense guidance to $420M-$440M (from $450M-$470M)
- GAAP operating profit of $98.5M; Non-GAAP operating profit of $113.2M
- Cash, cash equivalents and investments totaled $352.6M at June 30, 2026
- Completed enrollment in ALPHA-ORBIT pivotal navenibart study; top-line data expected Q3 2027
- Began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026
- Announced discontinuation of internal discovery programs and closure of Birmingham facility
Financial Impact
Q2 2026 GAAP EPS of $0.30 vs $0.23 consensus (beat by $0.07); total revenue of $218.3M vs $183.3M consensus (beat by $35.0M)
Risk Factors
- Core ORLADEYO revenue growth is decelerating (1% YoY reported, 10% comparable) and guidance was not raised
- Navenibart is still investigational with pivotal data not expected until Q3 2027 — binary risk
- Restructuring/discontinuation of internal discovery programs may signal limited pipeline depth
- Stockholders' deficit of $454.3M and accumulated deficit of $2.15B indicate ongoing balance sheet weakness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005223 |
| Document: f8k_080526.htm | 0001171843-26-005223 |
| Document: 0001171843-26-005223-index-headers.html | 0001171843-26-005223 |
| Document: 0001171843-26-005223-index.html | 0001171843-26-005223 |
| Document: 0001171843-26-005223.txt | 0001171843-26-005223 |
| 8-K Data (Synthetic) | 0001171843-26-005223 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.14 (−10.25%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.14 (−14.76%) |
Jun 12, 2026 15w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.14 (−10.15%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.14 (−6.44%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.14 (−6.86%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.14 (−15.21%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.14 (−7.81%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.14 (−11.52%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.14 (−8.95%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.14 (−13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access